CYP3A5 contributes to PDAC chemoresistance
Author:
Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,Hepatology
Link
http://www.nature.com/articles/nrgastro.2016.36.pdf
Reference1 articles.
1. Noll, E. M. et al. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nat. Med. http://dx.doi.org/10.1038/nm.4038
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Protocol of the IntenSify‐Trial: An open‐label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab‐paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy;Clinical and Translational Science;2023-11-03
2. Positive feedback regulation of lncRNA TPT1‐AS1 and ITGB3 promotes cell growth and metastasis in pancreatic cancer;Cancer Science;2022-05-23
3. A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis;EBioMedicine;2021-09
4. UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1;Journal of Experimental & Clinical Cancer Research;2019-07-09
5. The expression levels of CYP3A4 and CYP3A5 serve as potential prognostic biomarkers in lung adenocarcinoma;Tumor Biology;2017-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3